Plasmodium falciparum: inhibition in vitro with lactoferrin, desferriferrithiocin, and desferricrocin.
The microbial iron chelators desferriferrithiocin and desferricrocin as well as human lactoferrin were tested in vitro against Plasmodium falciparum. The microbial chelators inhibit the growth of P. falciparum in a dose dependent way. Parasite multiplication is stopped at 25-30 microM desferriferrithiocin, whereas 60-90 microM desferricrocin are needed to exhibit the same effect. After iron saturation, the microbial chelators are ineffective. Human lactoferrin (30 microM), both iron free and iron saturated, inhibits P. falciparum. A 3-day preincubation of host erythrocytes with iron free and iron saturated lactoferrin prior to infection enhances this effect, which is therefore attributed to lactoferrin bound iron. It has been suggested that the lactoferrin/iron complex generates oxygen free radicals, which may cause membrane damage of both erythrocyte and parasite. This process can be considered to lead to growth inhibition of the parasite.
D000818:Animals; D023181:Antimicrobial Cationic Peptides; D003676:Deferoxamine / Q000494:pharmacology; D004912:Erythrocytes / Q000469:parasitology; D006801:Humans; D007502:Iron Chelating Agents / Q000494:pharmacology*; D007781:Lactoferrin / Q000494:pharmacology*; D007782:Lactoglobulins / Q000494:pharmacology*; D010455:Peptides / Q000494:pharmacology*; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000254:growth & development; D011725:Pyridines; D013844:Thiazoles
D023181:Antimicrobial Cationic Peptides; D007502:Iron Chelating Agents; D007782:Lactoglobulins; D010455:Peptides; D011725:Pyridines; D013844:Thiazoles; C015790:desferri-ferricrocin; C050955:desferriferrithiocin; D007781:Lactoferrin; D003676:Deferoxamine